|1.||Lip, Gregory Y H: 21 articles (12/2015 - 01/2012)|
|2.||Giugliano, Robert P: 15 articles (12/2015 - 10/2010)|
|3.||Shi, Minggao: 14 articles (06/2015 - 09/2010)|
|4.||Antman, Elliott M: 11 articles (12/2015 - 10/2010)|
|5.||Mercuri, Michele: 11 articles (11/2015 - 10/2010)|
|6.||Ruff, Christian T: 10 articles (12/2015 - 10/2010)|
|7.||Mendell, Jeanne: 9 articles (10/2014 - 09/2010)|
|8.||Braunwald, Eugene: 8 articles (10/2015 - 10/2010)|
|9.||Morishima, Yoshiyuki: 8 articles (02/2015 - 12/2011)|
|10.||Murphy, Sabina A: 7 articles (10/2015 - 11/2013)|
10/01/2014 - "Although rapidly cleared, strategies to reverse edoxaban-mediated effects on anticoagulation are needed in cases of excessive bleeding or emergency. "
06/06/2015 - "We aim to assess whether adjustment of edoxaban dose in this trial prevented excess drug concentration and the risk of bleeding events. "
01/01/2014 - "Subgroup analyses indicated that RRs of edoxaban 30, 60 or 120 mg/d were 0.67 (p<0.001), 0.87 (p<0.001) and 3.3 (p = 0.004) respectively in major or clinically relevant nonmajor bleeding; 0.71 (p<0.001), 0.89 (p<0.001) and 2.29 (p = 0.002) respectively in any bleeding; as well as 0.86 (p = 0.01), 0.87 (p = 0.01) and 0.28 (p = 0.41) respectively in cardiovascular death… Meanwhile, paramount to note that pooled results other than the largest trial showed edoxaban was still associated with a decrease in the rate of major or clinically relevant nonmajor bleeding event (p = 0.02) and any bleeding (p = 0.002), but neither in all-cause death (p = 0.66) nor cardiovascular death (p = 0.70). "
01/01/2014 - "Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials."
09/01/2013 - "However, recent pharmacokinetic analyses of a phase II study with edoxaban in AF found that bleeding, with the same daily dosing, was less frequent with once daily dosing than with twice daily dosing, and correlated - better than other pharmacokinetic parameters - through drug concentrations. "
07/01/2015 - "Edoxaban is a safe and effective anticoagulant to reduce the risk of stroke in patients with NVAF and for the treatment of VTE."
12/01/2015 - "The latter class includes edoxaban, which has recently been approved for stroke prevention in AF by the United States Food and Drug Administration and the European Medicine Agency. "
11/01/2015 - "Cost-Effectiveness Of Edoxaban Compared With Other Licensed Noacs For The Prevention Of Stroke And Systemic Embolic Events In The Uk."
08/01/2015 - "With overall reduced risk of ischemic stroke and ICH, both edoxaban doses bring a NCB of mean (SD) 1.68 (0.15) saved events per 100 patients per year compared to anti-platelet drugs in a clinical trial population. "
08/01/2015 - "We hypothesised that edoxaban has a better net clinical benefit (NCB, balancing the reduction in stroke risk vs increased risk of haemorrhage) than no treatment or anti-platelet agents. "
12/01/2015 - "Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials."
11/01/2014 - "The aim of this study was to evaluate the population pharmacokinetics (PK) and exposure-response relationship of edoxaban in patients with non-valvular atrial fibrillation (AF). "
12/15/2015 - "Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study."
10/01/2015 - "Therefore, edoxaban is an effective and well tolerated therapeutic option in patients with nonvalvular atrial fibrillation. "
10/01/2015 - "Edoxaban: a review in nonvalvular atrial fibrillation."
12/01/2015 - "Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study."
09/01/2015 - "Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial."
03/01/2014 - "The review places the results of recent clinical trials that have evaluated the antithrombotic potential of edoxaban versus standard antithrombotic therapies in the prophylaxis and treatment of venous thromboembolism into perspective. "
07/01/2013 - "Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials."
11/05/2014 - "These data demonstrate the potential of edoxaban as an oral anticoagulant in the acute treatment of venous thromboembolism. "
01/01/2015 - "From 10 randomly selected subjects participating in the edoxaban Thrombus Reduction Imaging Study (eTRIS), total thrombus volume in the entire lower extremity deep venous system was quantified bilaterally. "
11/05/2014 - "QD administration of edoxaban including lower doses (1-10mg/kg) significantly reduced thrombus weight. "
06/01/2013 - "In contrast, edoxaban was equipotent in preventing thrombus formation in both wild-type and AT-deficient mice. "
09/01/2012 - "The 50% thrombus inhibition dose (ED(50)) was 1.9 mg/kg. At supra-therapeutic doses (10 and 20mg/kg), edoxaban significantly but moderately (less than 2-fold) prolonged bleeding time. "
09/01/2012 - "Edoxaban at 0.3, 1 and 3mg/kg exerted dose-dependent and significant inhibition of venous thrombus formation. "
|4.||Factor Xa (Coagulation Factor Xa)
|1.||Hip Replacement Arthroplasty (Total Hip Replacement)
|3.||Knee Replacement Arthroplasty (Total Knee Replacement)
|4.||Cardiac Resynchronization Therapy
|5.||Electric Countershock (Cardioversion)